PierluigiPorcuMD

Hematologic Oncology

Professor of Medical Oncology, Division Director of Hematologic Malignancies, and IRT Program Leader, Sidney Kimmel Cancer Center at Jefferson

Join to view full profile

Dr. Porcu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Porcu's full profile

Already have an account?

Office
925 Chestnut St
Ste 420A
Philadelphia, PA 19107
Phone+1 215-955-8874

Fax+1 215-955-2340

Summary

Dr. Pierluigi Porcu is a medical oncologist and physician scientist with a research focus in T-cell and NK-cell lymphoma and EBV-associated lymphomas. He is Division Director, Heme Malignancies and Hematopoietic Stem Cell transplantation and Program Leader, Immune Cell Regulation and Targeting at the Sidney Kimmel Cancer Center at Thomas Jefferson University, in Philadelphia, PA. He received his medical degree from University of Torino Faculty of Medicine and has been in academic practice in the US more than 20 years. He specializes in T-cell and NK-cell lymphomas and is an expert in the development of new therapies for blood cancers.

2013 ASH - Interview with Pierluigi Porcu, MD - Former CLF Board Member

Interview with with former CLF Board Member Pierluigi Porcu, MD, OSU Comprehensive Cancer Center.

Meet Team Buckeye: PG Porcu, MD

Associate Professor PG Porcu, MD, rides in Pelotonia for his patients. Hear why he thinks Pelotonia is such an important experience. 100% of all funds raised by

2015 Detroit PEF - Q&A with Clinician Panel

The question and answer session with our guest clinicians recorded at our Patient Educational Forum held in Detroit, Michigan.

Cutaneous Lymphomas: Diagnosis and Staging

Overview of how cutaneous lymphoma is diagnosed and classified; plus an explanation of staging.

Dr. Porcu Discusses CTCL

Pierluigi Porcu, MD, associate professor of internal medicine, Division of Hematology, Department of Internal Medicine, Wexner Medical Center, The Ohio State Un

ASH 2013 - PierLuigi Porcu, M.D., and the Cutaneous Lymphoma Foundation.

From ASH 2013, PierLuigi Porcu, M.D., discusses the Cutaneous Lymphoma Foundation's commitment to funding promising research with it's CLARIONS research awards

Debate: What is the best approach for relapsed T cell lymphoma? - AlloSCT

The continued evolution and refinement of strategies for disease diagnosis, risk assessment, therapeutic intervention and disease management have provided patie

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1999
Indiana University School of MedicineResidency, Internal Medicine, 1993 - 1996
University of Torino Faculty of MedicineClass of 1987

Certifications & Licensure

NJ State Medical License 2019 - 2025
PA State Medical License 2016 - 2024
OH State Medical License 1999 - 2018

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
SmithKline Beecham Research Fellowship award Inidiana University
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 1
Open Label Study of ONTAK (Denileukin Diftitox, DAB389 IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Start of enrollment: 2004 Nov 01
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas Start of enrollment: 2004 Mar 01
Completed
Phase 1
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2010 May 01
Completed
Phase 1
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2011 Oct 13
Completed
Phase 2
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2012 Feb 09
Completed
Phase 1, Phase 2
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
Completed
Phase 1
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
Completed
Phase 1
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Start of enrollment: 2017 Mar 08
Recruiting
Phase 1, Phase 2
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. Start of enrollment: 2018 Oct 14
Recruiting
Join now to see all

Publications & Presentations

PubMed

633 citations
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody
Don M. Benson, Courtney E. Bakan, Anjali Mishra, Craig C. Hofmeister, Yvonne A. Efebera
Blood. 2010-09-30
74 citations
A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma
Khuda D. Khan, Christos Emmanouilides, Don M. Benson, Deborah Hurst, Pablo Garcia
Clinical Cancer Research. 2006-12-01
36 citations
Non-Hodgkin’s Lymphomas, Version 2.2014
Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani
Journal of the National Comprehensive Cancer Network. 2014-06-01

Journal Articles

Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORIC
Pierluigi Porcu, MD, European Journal of Cancer
Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study
Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 Study
Pierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer

Abstracts/Posters

Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ...
Pierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Prospective Cohort of Black Patients with Mycosis Fungoides and S_zary Syndrome: Subset Analysis of the Mavoric Trial
Pierluigi Porcu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.
2019 ASCO Annual Meeting - 6/1/2019
Efficacy of Mogamulizumab By Prior Systemic Therapy in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis from the Phase 3 Mavoric Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Efficacy and Safety from the Copanlisib CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Safety of Venetoclax (Ven) + Rituximab (R) or Ven + Bendamustine (B) + R Randomized Versus B + R in Patients (pts) with Relapsed/Refractory (R/R) Follicul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Quality of life in cutaneous Ta cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: Results from the phase 3 MAVORIC trial.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Authored Content

SOHO 2021: A Rapidly Changing Treatment Landscape in Classical Hodgkin’s LymphomaSeptember 2021
Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat: Results from MAVORICAugust 2018
IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 StudyAugust 2018
Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018
Join now to see all

Press Mentions

Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of Its Recent End of Phase 2 Meeting with the FDADecember 7th, 2020
Viracta Announces Oral Presentation on Lead Program for EBV-Associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual MeetingNovember 6th, 2019
Treatment Delays with CAR-T Therapy: A High Price to PaySeptember 11th, 2019
Join now to see all